medigraphic.com
ISSN 2007-8013 (Print)
Órgano oficial de la Universidad Autónoma de Sinaloa

2021, Number 2

<< Back Next >>

Rev Med UAS 2021; 11 (2)

Lepromatous leprosy with type II reaction, panorama of a millennial disease in the XXI century: Case presentation

Inzunza-Cervantes G; García-Tinoco RM, Ahumada-Félix SR, Valenzuela-Delgado SY, Peña-Valenzuela AN

Language: Spanish
References: 46
Page: 136-147
PDF size: 357.34 Kb.


ABSTRACT

Leprosy is a chronic infectious-contagious systemic granulomatous disease, potentially curable, acquired by people susceptible to Mycobacterium leprae, with neurodermatological predilection, of high socioeconomic impactits diagnosis is based on clinical and epidemiological presumption, bacteriological, histopathology and immunological studies; during its chronic course 30-50% of patients may present exacerbation of established lesions or generation of new ones, consistent with immune reactions, called lepromatous reactions. Its treatment is based on the use of multidrug therapy schemes and during targeted therapy exacerbation according to the type of lepromatous reaction. Through the presentation of the clinical case and review of the literature, we investigated key elements that improve the understanding, diagnosis and treatment of lepromatous leprosy with type II reaction. Leprosy is an area of opportunities and great challenges, which through the strengthening of prevention, detection, diagnosis and timely treatment actions is curable and potentially eradicable.


REFERENCES

  1. Reibel F, Cambau E, Aubry A. Update on theepidemiology, diagnosis, and treatment of leprosy.Med Mal Infect 2015;45(9):383–93.

  2. Fischer M. Leprosy – an overview of clinicalfeatures, diagnosis, and treatment. J DtschDermatol Ges 2017;15(8):801–27.

  3. White C, Franco C. Leprosy in the 21st century.Clin Microbiol Rev 2015;28(1):80–94.

  4. Alberto C, Córdova B, Claxton M. Lepra lepromatosa:presentación de caso. Rev MédElectrón 2012;34(4):496–502.

  5. Cardona N, Bedoya G. Lepra: enfermedadmilenaria y actual. Iatreia 2011;24(1):51–64.

  6. Quevedo I, Yanez A, Delgado O, DominguezC BH. Some clinical-epidemiological aspectsof Hansen’s disease in the Yara. RM [revistaen Internet] 2019;23(1):11–21.

  7. Hoyos C, Cardona N. Reacciones leprosasLeprosy reactions. Reacciones leprosasCES Medicina 2016;30(2):200–209.

  8. Abreu G, Escalona R. Caracterización clinicoepidemiológicade pacientes con estadosreaccionales de lepra. MEDISAN 2015;2015;19(7):852–60.

  9. Chavarro B, Yesid C, Guerrero M. Mycobacteriumleprae’s evolution and environmentaladaptation. Acta Trop.2019;197(May):105041.

  10. Cardona N. Lepra: una revisión del estadodel arte. Med. Lab. 2012;18(1):11–24.

  11. Rodrigues L, Lockwood. Leprosy now: Epidemiology,progress, challenges, and researchgaps. Lancet Infect Dis2011;11(6):464–70.

  12. Muñoz L, Corrales L, Hernandez R, NavarreteJ. La lepra: Patología con concienciahistórica. Enf Infec Microbiol 2013;33(1):32–43.

  13. Zúñiga M, Bertoló M, Arias F, Torres S,Poulain C, Avendaño M, et al. Manual De OrganizaciónY Procedimientos Para La Lepra(Enfermedad De Hansen). Santiago ChileMinisterio de Salud 2017;1–61.

  14. Pinheiro R, Salles J, Sarno E, Sampaio E.Mycobacterium leprae–host-cell interactionsand genet. Future Microbiol. 2011;6(2):217–30.

  15. Secretaría de Salud de Mexico. Programa deAcción Específico Eliminación de la Lepra2013-2018. CENAPRECE 2013;1–76.

  16. Sauer M, Salomão H, Ramos G, EspindulaH, Rodrigues R, Macedo W, et al. Geneticsof leprosy: Expected and unexpected developmentsand perspectives. Clin. Dermatol2015;33(1):99–107.

  17. Gomez P. Primer Caso Clínico De Lepra.Rev Med Cos Cen 2016;LXXIII(618):179–84.

  18. Espinosa L, Romero A, Atoche C, Flores I.Reacción leprosa tipo 1 (reversa). DermatolRev Mex. 2015;59(1):54–61.

  19. Tiraboschi N, Fragoso C. Leprosy, a neglecteddisease that causes a wide variety of clinicalconditions in tropical countries. Mem.Inst. Oswaldo Cruz [en línea]

  20. 2012;107(1):28–33.20. Rodrigues J, Nacagami M, Simões J. LeprosyAs a Complex Infection: Breakdown ofthe Th1 and Th2 Immune Paradigm in theImmunopathogenesis of the Disease. FrontImmunol 2017;8:18–21.

  21. Fragozo L, Villalobos C. Enfermedad deHansen (lepra): Eritema nodoso leproso.Presentación de caso. Biociencias.2017;12(1):101–8.

  22. Bhat R, Prakash C. Leprosy: An overview ofpathophysiology. Interdiscip Perspect InfectDis. 2012;2012:1–7.

  23. World Health Organization. Global LeprosyStrategy 2016-2020: Accelerating Towards aLeprosy-free World. 2016. 1–21.

  24. Colorado C, Sánchez G, Guerrero M, LeónC. Confiabilidad y concordancia de dos escalasde lectura de baciloscopias para clasificacióny seguimiento del tratamiento conmúltiples medicamentos de los pacientescon lepra. Biomedica. 2011;31(3):403–9.

  25. Guillén G. Estado actual de la lepra. SEHER2016;6(2):2016.

  26. Torres E, Vargas F, Atoche C, Arrazola J,Lepra, Arenas R. Clasificación y cuadro clínico.Dermatol Rev Mex. 2012;66(1):47–54.

  27. Silva C, Belisle J. Host lipid mediators in leprosy:The hypothesized contributions topathogenesis. Frontiers in Immunology2018;9(134):1–15.

  28. Sousa T, Rodrigues J, Semblano A, MagnoL, Simões J. Nerve growth factor and pathogenesisof leprosy: Review and update.Front Immunol 2018;9:1–8.

  29. Elwan N, Neinaa Y. Borderline LepromatousLeprosy: Uncommon Clinical Presentation.Am J Dermatopathol 2019;41(3):211–3.

  30. Uaska P, Penna G, Bührer S, Pontes M,Gonçalves H, Cruz R, et al. Human GeneticSusceptibility of Leprosy Recurrence. SciRep. 2020;10(1):1–5.

  31. Montaño G, Lancheros P, Celis L. Recidivade lepra y reacción tipo II en paciente tratadocon poliquimioterapia (PQT). Nova [online]2014;12(21):109–14.

  32. Serrano H, Cardona N. Neuropatía leprótica:una mirada integral de la afección periféricacausada por Mycobacterium leprae. SaludUninorte. Barranquilla 2017;33(3):451–63.

  33. Sharma R, Lahiri R, Scollard D, Pena M, WilliamsD, Adams L, et al. The armadillo: Amodel for the neuropathy of leprosy and potentiallyother neurodegenerative diseases.Dis Model Mech 2013;6(1):19–24.

  34. Kundakci N, Erdem C. Leprosy: A great imitator.Clin Dermatol 2019;37(3):200–212.

  35. Pandhi D, Chhabra N. New insights in thepathogenesis of type 1 and type 2 lepra reaction.Indian J Dermatol Venereol Leprol2013;79(6):739–49.

  36. Carneiro S, Nakasato FK, Balassiano V, etal. Lepromatous Reaction Type II: Clinicaland Laboratory Aspects. Skinmed2019;17(4):261–5.

  37. Ray A, Sen S, Banerjee S, Mukhopadhyay J.Type II lepra reaction--an unusual presentation.J Assoc Physicians India 2012;60:45–7.

  38. Sharma P, Kumar A, Tuknayat A, Thami G.Lucio Phenomenon: A Rare Presentation ofHansen’s Disease. J Clin Aesthet Dermatol.2019;12(12):35–8.

  39. Torres E, Vargas F, Enrique C, Arrazola J,Arenas R. Lepra. Técnicas diagnósticas yestrategias terapéuticas. Dermatol Rev Mex2012;56(2):119–25.

  40. Toro A, Vielma S, Petrosino P MM. Lepra lepromatosa.A propósito de un caso clínico.Avances en Biomedicina 2014;3(3):158–64.

  41. Gutierrez F, Valle R, Kenia M, Fernández M.Comportamiento De Los Pacientes ConDiagnóstico Tardío De Lepra. Camaguey,Cuba, 2015. Fontilles Rev. leprol.2016;30(6):571-590.

  42. Martinez J, Cardenas J. Treatment of Leprosyand Leprosy Reactions. Curr Treat OptionsInfect Dis 2017;9(3):287–98.

  43. Eichelmann K, González S, Salas J,Ocampo J. Lepra: puesta al día. Definición,patogénesis, clasificación, diagnóstico y tratamiento.Actas Dermosifiliogr.2013;104(7):554–63.

  44. Gautam C, Jaiswal A. Forgetting the CardinalSign is a Cardinal Sin: Slit-skin SmearWhat. Indian J Paediatr Dermatol2019;20(4):341–4.

  45. Vasquez D, Cuevas S, Faizal M. Resistenciaa la poliquimioterapia en pacientes con enfermedadde Hansen. Rev. Salud Pública2017;19(6):814–7.

  46. Kamath S, Vaccaro S, Rea T, Ochoa M. Recognizingand managing the immunologicreactions in leprosy. J Am Acad Dermatol2014;71(4):795–803.




2020     |     www.medigraphic.com